ZeroStack Corp. operates a hybrid model combining decentralized AI treasury management—centered on strategic holdings of the 0G Token—and wholesale pharmaceutical distribution through its subsidiary Phatebo. The latest quarterly filing highlights ongoing liquidity constraints with a current ratio under 1, tempered by fresh private placements and cryptocurrency financings that bolster capital but introduce valuation volatility. While pharmaceutical sales provide near-term cash flows recognized at product transfer, the company remains highly exposed to fluctuating digital asset values impacting reported earnings. Regulatory compliance and cybersecurity emerge as persistent operating risks across both verticals, while execution on growth initiatives hinges on integration success and expanding pharmaceutical geographic reach.